Ankylosing Spondylitis Treatment Market by Drug Type - Global Industry Analysis & Forecast to 2027
Published On : November 2020 Pages : 154 Category: Pharma & Healthcare Report Code : HC1213755
Ankylosing Spondylitis Treatment Market By Drug Type (Cosentyx, Humira, Simponi, Remicade, Enbrel, Cimzia) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Ankylosing Spondylitis Treatment Markethas encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Ankylosing Spondylitis is a chronic autoimmune disorder that often lasts a lifetime. Drug treatment methods may help to reduce these complications as well as the progression of the disorder.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Ankylosing Spondylitis Treatment Market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- AbbVie, Inc.
- Amgen, Inc.
- Pfizer, Inc.
- Novartis AG
- Eli Lilly and Company
- UCB, Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Ankylosing Spondylitis Treatment Market, ByDrugType, Estimates and Forecast, 2017-2027 ($Million)
o Cosentyx
o Humira
o Simponi
o Remicade
o Enbrel
o Cimzia
· Ankylosing Spondylitis Treatment Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o AbbVie, Inc.
o Amgen, Inc.
o Pfizer, Inc.
o Novartis AG
o Eli Lilly and Company
o UCB, Inc.
o Johnson & Johnson Services, Inc.
o Merck & Co., Inc.
· Ankylosing Spondylitis Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Ankylosing Spondylitis Treatment Market, By Country
o U.S. Ankylosing Spondylitis Treatment Market
o Canada Ankylosing Spondylitis Treatment Market
o Mexico Ankylosing Spondylitis Treatment Market
o Europe
§ Europe Ankylosing Spondylitis Treatment Market, By Country
o UK Ankylosing Spondylitis Treatment Market
o Germany Ankylosing Spondylitis Treatment Market
o France Ankylosing Spondylitis Treatment Market
o Russia Ankylosing Spondylitis Treatment Market
o Italy Ankylosing Spondylitis Treatment Market
o Rest of Europe Ankylosing Spondylitis Treatment Market
o Asia-Pacific
§ Asia-Pacific Ankylosing Spondylitis Treatment Market, By Country
o China Ankylosing Spondylitis Treatment Market
o Japan Ankylosing Spondylitis Treatment Market
o South Korea Ankylosing Spondylitis Treatment Market
o India Ankylosing Spondylitis Treatment Market
o Southeast Asia Ankylosing Spondylitis Treatment Market
o Rest of Asia-Pacific Ankylosing Spondylitis Treatment Market
o South America
§ South America Ankylosing Spondylitis Treatment Market
o Brazil Ankylosing Spondylitis Treatment Market
o Argentina Ankylosing Spondylitis Treatment Market
o Columbia Ankylosing Spondylitis Treatment Market
o Rest of South America Ankylosing Spondylitis Treatment Market
o Middle East and Africa
§ Middle East and Africa Ankylosing Spondylitis Treatment Market
o Saudi Arabia Ankylosing Spondylitis Treatment Market
o UAE Ankylosing Spondylitis Treatment Market
o Egypt Ankylosing Spondylitis Treatment Market
o Nigeria Ankylosing Spondylitis Treatment Market
o South Africa Ankylosing Spondylitis Treatment Market
o TurkeyAnkylosing Spondylitis Treatment Market
o Rest of MEA Ankylosing Spondylitis Treatment Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Ankylosing Spondylitis Treatment Market, By Drug Type
5.1. Introduction
5.2. Global Ankylosing Spondylitis Treatment Revenue and Market Share by Drug Type (2017-2021)
5.2.1. Global Ankylosing Spondylitis Treatment Revenue and Revenue Share by Drug Type (2017-2021)
5.3. Cosentyx
5.3.1. Global Cosentyx Revenue and Growth Rate (2017-2021)
5.4. Humira
5.4.1. Global Humira Revenue and Growth Rate (2017-2021)
5.5. Simponi
5.5.1. Global Simponi Revenue and Growth Rate (2017-2021)
5.6. Remicade
5.6.1. Global Remicade Revenue and Growth Rate (2017-2021)
5.7. Enbrel
5.7.1. Global Enbrel Revenue and Growth Rate (2017-2021)
5.8. Cimzia
5.8.1. Global Cimzia Revenue and Growth Rate (2017-2021)
6. Ankylosing Spondylitis Treatment Market, By Region
6.1. Introduction
6.2. Global Ankylosing Spondylitis Treatment Revenue and Market Share by Regions
6.2.1. Global Ankylosing Spondylitis Treatment Revenue by Regions (2017-2021)
6.3. North America Ankylosing Spondylitis Treatment by Countries
6.3.1. North America Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2021)
6.3.2. North America Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2021)
6.3.3. United States
6.3.3.1. United States Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.4. Canada
6.3.4.1. Canada Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.3.5. Mexico
6.3.5.1. Mexico Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4. Europe Ankylosing Spondylitis Treatment by Countries
6.4.1. Europe Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2021)
6.4.2. Europe Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2021)
6.4.3. Germany
6.4.3.1. Germany Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.4. France
6.4.4.1. France Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.5. UK
6.4.5.1. UK Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.6. Russia
6.4.6.1. Russia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.7. Italy
6.4.7.1. Italy Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5. Asia-Pacific Ankylosing Spondylitis Treatment by Countries
6.5.1. Asia-Pacific Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2021)
6.5.2. Asia-Pacific Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2021)
6.5.3. China
6.5.3.1. China Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.4. Japan
6.5.4.1. Japan Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.5. Korea
6.5.5.1. Korea Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.6. India
6.5.6.1. India Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.6. South America Ankylosing Spondylitis Treatment by Countries
6.6.1. South America Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2021)
6.6.2. South America Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2021)
6.6.3. Brazil
6.6.3.1. Brazil Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.4. Argentina
6.6.4.1. Argentina Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.5. Columbia
6.6.5.1. Columbia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7. Middle East and Africa Ankylosing Spondylitis Treatment by Countries
6.7.1. Middle East and Africa Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2021)
6.7.2. Middle East and Africa Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2021)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.5. Egypt
6.7.5.1. Egypt Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.6. Nigeria
6.7.6.1. Nigeria Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.7. South Africa
6.7.7.1. South Africa Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.8. Turkey
6.7.8.1. Turkey Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2021)
7. Company Profiles
7.1. AbbVie, Inc.
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Amgen, Inc.
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Pfizer, Inc.
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Novartis AG
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Eli Lilly and Company
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. UCB, Inc.
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. Johnson & Johnson Services, Inc.
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
7.8. Merck & Co., Inc.
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Financial Overview
8. Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.1. Global Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2022-2027)
8.2. Ankylosing Spondylitis Treatment Market Forecast by Regions (2022-2027)
8.2.1. North America Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.1.1. United States Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.1.2. Canada Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.1.3. Mexico Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2. Europe Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.1. Germany Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.2. France Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.3. UK Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.4. Russia Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.5. Italy Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.2.6. Rest of Europe Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3. Asia-Pacific Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.1. China Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.2. Japan Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.3. Korea Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.4. India Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.5. Southeast Asia Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.3.6. Rest of Asia-Pacific Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.4. South America Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.4.1. Brazil Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.4.2. Argentina Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.4.3. Columbia Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.4.4. Rest of South America Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5. Middle East and Africa Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.1. Saudi Arabia Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.2. United Arab Emirates Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.3. Egypt Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.4. Nigeria Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.5. South Africa Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.6. Turkey Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.2.5.7. Rest of Middle East and Africa Ankylosing Spondylitis Treatment Market Forecast (2022-2027)
8.3. Ankylosing Spondylitis Treatment Market Forecast by Drug Type (2022-2027)
8.3.1. Ankylosing Spondylitis Treatment Forecast by Drug Type (2022-2027)
8.3.2. Ankylosing Spondylitis Treatment Market Share Forecast by Drug Type (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Treatment Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Ankylosing Spondylitis Treatment Revenue and Revenue Share by Drug Type (2017-2019)
Figure Global Cosentyx Revenue and Growth Rate (2017-2019)
Figure Global Humira Revenue and Growth Rate (2017-2019)
Figure Global Simponi Revenue and Growth Rate (2017-2019)
Figure Global Remicade Revenue and Growth Rate (2017-2019)
Figure Global Enbrel Revenue and Growth Rate (2017-2019)
Figure Global Cimzia Revenue and Growth Rate (2017-2019)
Table Global Ankylosing Spondylitis Treatment Revenue by Regions (2017-2019)
Figure North America Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure North America Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2019)
Figure North America Ankylosing Spondylitis Treatment by Countries (2017-2019)
Figure North America Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure United States Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure United States Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Canada Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Mexico Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Europe Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2019)
Figure Europe Ankylosing Spondylitis Treatment by Countries (2017-2019)
Figure Europe Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Germany Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Germany Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure France Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure UK Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Russia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Italy Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Rest of Europe Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Asia-Pacific Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Ankylosing Spondylitis Treatment by Countries (2017-2019)
Figure Asia-Pacific Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure China Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure China Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Japan Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Korea Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure India Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Southeast Asia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure South America Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2019)
Figure South America Ankylosing Spondylitis Treatment by Countries (2017-2019)
Figure South America Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Brazil Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Argentina Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Columbia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Rest of South America Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Middle East and Africa Ankylosing Spondylitis Treatment Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Ankylosing Spondylitis Treatment by Countries (2017-2019)
Figure Middle East and Africa Ankylosing Spondylitis Treatment Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Saudi Arabia Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure United Arab Emirates Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Egypt Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Nigeria Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure South Africa Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Turkey Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Treatment Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2017-2019)
Table AbbVie, Inc. Ankylosing Spondylitis Treatment Financial Overview
Table Amgen, Inc. Ankylosing Spondylitis Treatment Financial Overview
Table Pfizer, Inc. Ankylosing Spondylitis Treatment Financial Overview
Table Novartis AG Ankylosing Spondylitis Treatment Financial Overview
Table Eli Lilly and Company Ankylosing Spondylitis Treatment Financial Overview
Table UCB, Inc. Ankylosing Spondylitis Treatment Financial Overview
Table Johnson & Johnson Services, Inc. Ankylosing Spondylitis Treatment Financial Overview
Table Merck & Co., Inc. Ankylosing Spondylitis Treatment Financial Overview
Figure Global Ankylosing Spondylitis Treatment Revenue (Millions USD) and Growth Rate (2019-2027)
Table Ankylosing Spondylitis Treatment Market Forecast by Regions (2019-2027)
Figure North America Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure United States Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Canada Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Mexico Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Europe Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Germany Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure France Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure UK Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Russia Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Italy Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Rest of Europe Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Asia-Pacific Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure China Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Japan Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Korea Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure India Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Southeast Asia Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure South America Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Brazil Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Argentina Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Columbia Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Rest of South America Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Middle East and Africa Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Saudi Arabia Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure United Arab Emirates Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Egypt Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Nigeria Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure South Africa Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Turkey Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Treatment Market Forecast (2019-2027)
Figure Global Ankylosing Spondylitis Treatment Forecast by Drug Type (2019-2027)
Figure Global Ankylosing Spondylitis Treatment Market Share Forecast by Drug Type (2019-2027)
Figure Global Ankylosing Spondylitis Treatment Forecast by Drug Type (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|